In our study, we investigated the impact of S100A4 on microglial function in AD, demonstrating that S100A4 knockdown facilitated a shift in the microglial activation profile, reducing the expression of pro-inflammatory mediators and enhancing markers associated with anti-inflammatory in BV2 cells following AbetaO treatment. The gene discussed is S100A4; the disease is Alzheimer disease.